Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, tolerability, PK and PD study of AX-0810 in healthy participants
NL-OMON60967Phase 1Completed
- Sponsor
- ProQR Therapeutics
- Start
- Nov 2025
- Modality
- Gene Editing → Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of PR1100 in cholestatic disease, sponsored by ProQR Therapeutics. Primary endpoint: Primary endpoint(s). Started Nov 2025; status: completed.
02
Drugs
PR1100
03
Conditions
cholestatic disease
Beyond the preview
Go deeper on NL-OMON60967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60967.